Galectin Therapeutics Inc. (OTC: PRWP) today announced that the European Patent Office has granted the Company a new patent, No. 02731178.6, "Co-administration of a Polysaccharide with a Chemotherapy for the Treatment of Cancer". The patent protects, among other things, methods for reducing the toxicity of chemotherapies in which a polysaccharide, such as the Company's GM-CT-01 (DAVANAT®), is co-administered with a chemotherapeutic agent to reduce toxicity of the chemotherapy. This application is the seventh patent in Galectin Therapeutics growing patent portfolio that covers its core Galectin-targeting compounds and further reinforces the proprietary nature of its compounds.
“Co-administration of a Polysaccharide with a Chemotherapy for the Treatment of Cancer”
"We continue to strengthen our intellectual property portfolio beyond the U.S. We expect similar success with additional patent applications pending internationally," said Peter G. Traber, M.D., and Chief Executive Officer, Galectin Therapeutics. "The new patent covers the administration of a therapeutic agent to cancer patients to enhance efficacy while substantially reducing toxicity and the well-known, undesirable side effects suffered by most chemotherapy patients. The patent also allows claims for the composition of matter for GM-CT-01 itself.
"Our technology improves the efficacy and safety profile of chemotherapy by targeting galectins, which are proteins involved in the progression of cancer and fibrosis. Based on data in our own studies as well as third party studies at major international laboratories, we are confident that our galectin-targeting compounds will soon play a major role in advancing the treatment of cancer and liver fibrosis," said Anatole Klyosov, Ph.D., D.Sc., Chief Scientist, Galectin Therapeutics.
Innovative urine test could improve pancreatic cancer survival rates